Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature
ATP-binding cassette transporter B1 (ABCB1; P-glycoprotein; multidrug resistance protein 1)
is an adenosine triphosphate (ATP)-dependent efflux transporter located in the plasma …
is an adenosine triphosphate (ATP)-dependent efflux transporter located in the plasma …
[HTML][HTML] Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients
A Provenzani, A Santeusanio, E Mathis… - World Journal of …, 2013 - ncbi.nlm.nih.gov
The introduction of tacrolimus in clinical practice has improved patient survival after organ
transplant. However, despite the long use of tacrolimus in clinical practice, the best way to …
transplant. However, despite the long use of tacrolimus in clinical practice, the best way to …
Artificial neural network model for predicting the bioavailability of tacrolimus in patients with renal transplantation
K Thishya, KK Vattam, SM Naushad, SB Raju… - PLoS …, 2018 - journals.plos.org
The objective of the current study was to explore the role of ABCB1 and CYP3A5 genetic
polymorphisms in predicting the bioavailability of tacrolimus and the risk for post-transplant …
polymorphisms in predicting the bioavailability of tacrolimus and the risk for post-transplant …
Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients
A Provenzani, M Notarbartolo… - International …, 2011 - spandidos-publications.com
Tacrolimus is a substrate of cytochrome P4503A (CYP3A) enzymes as well as of the drug
transporter ABCB1. We have investigated the possible influence of CYP3A5 and ABCB1 …
transporter ABCB1. We have investigated the possible influence of CYP3A5 and ABCB1 …
Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers
HL Tang, HG Xie, Y Yao, YF Hu - Pharmacogenetics and …, 2011 - journals.lww.com
Background CYP3A5 genetic polymorphisms contribute to marked interindividual
differences in the metabolism of and response to tacrolimus in humans. Objective This study …
differences in the metabolism of and response to tacrolimus in humans. Objective This study …
Impacts of high intra-and inter-individual variability in tacrolimus pharmacokinetics and fast tacrolimus metabolism on outcomes of solid organ transplant recipients
Tacrolimus is a first-line calcineurin inhibitor (CNI) and an integral part of the
immunosuppressive strategy in solid organ transplantation. Being a dose-critical drug …
immunosuppressive strategy in solid organ transplantation. Being a dose-critical drug …
Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation
S Vannaprasaht, S Reungjui, D Supanya… - Clinical …, 2013 - Elsevier
Abstract Background Cytochrome P450 (CYP) 3A4 and 3A5 are major isoforms involved in
the metabolism of tacrolimus, with the CYP3A5 gene being more polymorphic. It is …
the metabolism of tacrolimus, with the CYP3A5 gene being more polymorphic. It is …
Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition
V Haufroid - Current drug targets, 2011 - ingentaconnect.com
The ATP-binding cassette (ABC) transporter superfamily comprises membrane proteins that
translocate a variety of substrates across extra-and intra-cellular membranes, and act as …
translocate a variety of substrates across extra-and intra-cellular membranes, and act as …
Association between ABCB1 polymorphisms and response to first-generation antiepileptic drugs in a Tunisian epileptic population
M Ajmi, S Boujaafar, N Zouari, D Amor… - International Journal …, 2018 - Taylor & Francis
Purpose: We aimed in this study to investigate the association between the ATP-Binding
Cassette sub-family B, member1 (ABCB1) polymorphisms: C1236T (rs1128503), G2677T …
Cassette sub-family B, member1 (ABCB1) polymorphisms: C1236T (rs1128503), G2677T …
Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A‐status in liver transplant patients
K Monostory, K Tóth, Á Kiss, E Háfra… - British Journal of …, 2015 - Wiley Online Library
Aims Inter‐individual variability in dose requirements of calcineurin inhibitors (CNI) has
been linked to genetic polymorphisms of CYP3A enzymes. CYP3A5* 3, CYP3A4* 1B and …
been linked to genetic polymorphisms of CYP3A enzymes. CYP3A5* 3, CYP3A4* 1B and …